Ovid Therapeutics grants 957,000 options to director

Ovid Therapeutics Inc. reported that director Jeremy M. Levin received a grant of employee stock options covering 957,000 shares of Ovid common stock.

Rhea-AI Filing Summary

Ovid Therapeutics Inc. reported that director Jeremy M. Levin received a grant of employee stock options covering 957,000 shares of Ovid common stock. These options were awarded as a form of compensation, not through an open-market purchase or sale.

According to the terms, the options will vest in 48 equal monthly installments starting on March 20, 2026. Vesting is conditioned on Levin’s continued service to the company through each vesting date, meaning he earns the right to exercise a portion of the options each month over a four-year period.

Insider Trade Summary

Grant/Award: 957,000 shares

Grant/Award 1 txn

Insider LEVIN JEREMY M

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Employee Stock Option (Right to Buy)	957,000	$0.00	$0.00

Holdings After Transaction: Employee Stock Option (Right to Buy) — 957,000 contracts (Direct)

Footnotes (1)

1. F1. The shares subject to the stock option will vest in 48 equal monthly installments commencing on March 20, 2026, subject to the Reporting Person's continued services through each such date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did OVID report for Jeremy M. Levin?

Ovid Therapeutics reported a grant of employee stock options to director Jeremy M. Levin for 957,000 shares of common stock. This was a compensation award, not an open-market purchase or sale of existing shares.

How many OVID stock options were granted to Jeremy M. Levin?

Jeremy M. Levin was granted employee stock options covering 957,000 shares of Ovid Therapeutics common stock. This entire amount represents a single option award reported in the Form 4 insider filing as an acquisition transaction.

What is the vesting schedule for Jeremy Levin’s OVID stock options?

The stock options granted to Jeremy Levin will vest in 48 equal monthly installments starting on March 20, 2026. Each monthly vesting requires his continued service to Ovid Therapeutics through the applicable vesting date.

Is Jeremy Levin’s OVID option grant a buy or sell transaction?

The transaction is reported as an acquisition by grant, not a buy or sell in the market. It reflects an employee stock option award under compensation arrangements, with no shares sold as part of this filing.

What role does Jeremy M. Levin hold at Ovid Therapeutics (OVID)?

In this filing, Jeremy M. Levin is identified as a director of Ovid Therapeutics. The reported Form 4 transaction relates to a director compensation stock option grant, rather than open-market trading in OVID shares.

When do Jeremy Levin’s OVID options start vesting?

The vesting of Jeremy Levin’s Ovid stock options begins on March 20, 2026. From that date, the award vests in 48 equal monthly installments, contingent on his ongoing service to the company during the vesting period.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/02/2026 - 04:30 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

LEVIN JEREMY M

(Last) (First) (Middle)

C/O OVID THERAPEUTICS INC.

441 NINTH AVENUE, 14TH FLOOR

(Street)

NEW YORK NY 10001

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Ovid Therapeutics Inc. [ OVID ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/26/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)	$1.65	02/26/2026		A		957,000		(1)	02/25/2036	Common Stock	957,000	$0	957,000	D

Explanation of Responses:

1. The shares subject to the stock option will vest in 48 equal monthly installments commencing on March 20, 2026, subject to the Reporting Person's continued services through each such date.

	/s/ Jeremy Levin	03/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.